Meeting NewsVideo

VIDEO: Checklist may help rheumatologists tackle 'evolving payment models'

DESTIN, Fla. — During a presentation at the 2018 Congress of Clinical Rheumatology, Jon Glaudemans, chief executive of United Rheumatology, emphasized that rheumatologists can learn from the alternative payment models piloted by the American Society of Clinical Oncology and the Renal Physicians Association, and provided a 7-point checklist for rheumatologists to follow in their own practices.

“If you have seen the news within the last week or so, you will have seen that the president and the Secretary of Health and Human Services have begun a reasserted approach to focusing on drug prices,” Glaudemans told Healio Rheumatology. “As rheumatologists, we are well-aware of the cost of those drugs and the expense to our patients and to society as a whole.”

“In the likely event that we will continue to see great uncertainty in how we are paid for the services we are providing, I decided to pull together a survey of what has happened in the oncology and nephrology spaces, focusing first on what CMS is doing in those two specialties with regard to new payment models that may change the way ‘buy-and-bill’ drugs are paid for, the way drugs are covered, and the way services are bundled both within the physician office, in the infusion suite, and any follow-on care,” he said.

 

 

DESTIN, Fla. — During a presentation at the 2018 Congress of Clinical Rheumatology, Jon Glaudemans, chief executive of United Rheumatology, emphasized that rheumatologists can learn from the alternative payment models piloted by the American Society of Clinical Oncology and the Renal Physicians Association, and provided a 7-point checklist for rheumatologists to follow in their own practices.

“If you have seen the news within the last week or so, you will have seen that the president and the Secretary of Health and Human Services have begun a reasserted approach to focusing on drug prices,” Glaudemans told Healio Rheumatology. “As rheumatologists, we are well-aware of the cost of those drugs and the expense to our patients and to society as a whole.”

“In the likely event that we will continue to see great uncertainty in how we are paid for the services we are providing, I decided to pull together a survey of what has happened in the oncology and nephrology spaces, focusing first on what CMS is doing in those two specialties with regard to new payment models that may change the way ‘buy-and-bill’ drugs are paid for, the way drugs are covered, and the way services are bundled both within the physician office, in the infusion suite, and any follow-on care,” he said.

 

 

    See more from Congress of Clinical Rheumatology Annual Meeting